This is a prospective observational study with the purpose of evaluating the durability of the bone cement repair used to treat spontaneous cerebrospinal fluid leaks (SCSFL). Long-term follow-up data will be collected from the EMR from standard of care procedures. Additionally, subjects will be asked to complete a one-time questionnaire related to their symptoms and health.THIS STUDY IS ENROLLING BY INVITATION ONLY - The study staff will screen for subject eligibility against the inclusion and exclusion criteria for all potential subjects. This will occur via chart review of scheduled clinic patients within the Neuroscience Center or hospital,. Some referrals may come from PI, clinical staff, and/or other research staff. Research staff will meet eligible patients to explain the study, review the consent form, ask the subject if they voluntarily agree to participate, and obtain consent.

Elevated lipoprotein(a) (Lp[a]) is recognized as an important risk factor for cardiovascular disease. However, there are currently no approved pharmaceutical interventions for Lp(a) lowering. Recent studies have demonstrated that muvalaplin effectively reduces Lp(a) and is well tolerated by study participants. This study will investigate the effect of muvalaplin on the reduction of major adverse cardiovascular events in adults with elevated Lp(a) who have either a prior atherosclerotic cardiovascular disease (ASCVD) event or are at risk for a first ASCVD event. This study will also provide additional evidence for the potential clinical benefits of muvalaplin in this population.The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.THIS STUDY IS ENROLLING BY INVITATION ONLY 

Researchers at Indiana University School of Medicine are looking for adults with concussion or mild traumatic brain injury (mTBI) to find out if a training program can help people have better emotional health and well-being.

 Study goals:To analyze the significance of treatment, clinical and molecular variables in predicting progression free survival (PFS) at 6 months (PFS6) from date of diagnosis.To create a well annotated ATRT biorepository for current and future studies through the collection of biospecimens, imaging and key clinical data.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632